2190.HK - Zylox-Tonbridge Medical Technology Co., Ltd.
| Previous close | 11.220 |
| Open | 11.200 |
| Bid | 11.260 x N/A |
| Ask | 11.340 x N/A |
| Day's range | 11.020 - 11.440 |
| 52-week range | 8.500 - 16.980 |
| Volume | |
| Avg. volume | 317,791 |
| Market cap | 3.769B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.380 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.67 |
PR NewswireZylox-Tonbridge to be Added to MSCI China All Shares Small Cap Index
On May 12, MSCI, a leading provider of critical decision support tools and services for the global investment community, announced the results of the May 2023 Index Review for the MSCI Equity Indexes. Zylox-Tonbridge (2190.HK, "the Company") is pleased to learn that the Company's stock will be added to the MSCI China All Shares Small Cap Index, effective as of the close of May 31, 2023.
PR NewswireZylox-Tonbridge enters into strategic cooperation with Hicicare for innovative Chinese vascular guidewires solutions
Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK, the "Company") announced the signing of a strategic agreement with Guangdong Hicicare Science Co., Ltd. ("Hicicare"). With the collaboration, Zylox-Tonbridge and Hicicare plan to introduce and help accelerate the commercialization of co-branded vascular guidewire products in the neuro- and peripheral-vascular interventional device market segments in a move to provide innovative vascular access solutions to Chinese physicians and patients.
PR NewswireZylox-Tonbridge Announces Financial Results for 2022: Revenue Increases by 87.8% YOY to RMB 334 million and Gross Profit Reaches RMB 253 million
On March 29, 2023, Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK, hereinafter referred to as the "Company") released its annual financial results for 2022. During the reporting period, the Company's operating revenue increased by 87.8% YOY to RMB 334 million. In particular, the neurovascular intervention business maintained rapid growth, with revenue rising 107.9% YOY to RMB 233 million. Revenue from the peripheral-vascular intervention business also showed a YOY gain of 53.4% to RMB 10
PR NewswireZylox-Tonbridge Assisted Turkish Hospitals in Post-earthquake Recovery
Zylox-Tonbridge Medical Technology Co., Ltd. (2190.HK, "the Company"), one of the leading players in the neuro- and peripheral-vascular interventional medical device market in China, announced its plans to provide free replacement services for products damaged in the recent earthquake that hit Turkey. The Company aims to meet the local patients' medical needs and support the recovery of hospitals in Turkey.
PR NewswireZylox-Tonbridge maintains strong revenue and gross profit growth, including gross margin improvement driven by its platform-based strategy in 1H22
On August 15, Zylox-Tonbridge (2190.HK, "the Company") released its 2022 interim results.